PDF herunterladen
Exp Clin Endocrinol Diabetes 2001; Vol. 109(1): 52-55
DOI: 10.1055/s-2001-11019
Article

© Johann Ambrosius Barth

Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma

J. W. A. Smit 1 , J. P. Schröder-van der Elst 1 , M. Karperien 1, 2 , I. Que 1 , J. A. Romijn 1 , D. van der Heide 3
  • 1 Department of Endocrinology and Metabolism and 2 Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
  • 3 Human and Animal Physiology Group, Wageningen University, Wageningen, The Netherlands
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2001 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary:

The uptake of iodide in thyroid epithelial cells is mediated by the sodium/iodide symporter (NIS). The uptake of iodide is of vital importance for thyroid physiology and is a prerequisite for radioiodine therapy in thyroid cancer. Loss of iodide uptake due to diminished expression of the human NIS (hNIS) is frequently observed in metastasized thyroid cancer. So far, no animal model for the study of radioiodine therapy in thyroid cancer has been available. Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. We have performed a stable transfection of hNIS into the hNIS defective follicular thyroid carcinoma cell line FTC133. Stabily transfected colonies exhibited high uptake of Na125I, which could be blocked completely with sodiumperchlorate. hNIS transfected FTC133 and non-transfected cell lines injected subcutaneously in nude mice formed tumors after 6 weeks. Iodide uptake in the hNIS transfected tumor was much higher than in non-transfected tumor, but a rapid release of radioactivity from the hNIS transfected tumor was observed. Further studies are necessary to investigate the role of hNIS in relation to other thyroid specific proteins in iodide metabolism in thyroid cancer.

Key words:

Iodide - sodium/iodide symporter - thyroid carcinoma - transfection

References

  • 1 Ambesi-Impiombato F S, Parks L A, Coon H G. Culture of hormone-dependent functional epithelial cells from rat thyroids.  Proc Natl Acad Sci USA. 77 3455-3459 1980; 
    CrossrefPubMedGoogle Scholar
  • 2 Arturi F, Russo D, Schlumberger M, du V J, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez H G, Filetti S. Iodide symporter gene expression in human thyroid tumors.  J Clin Endocrinol Metab. 83 2493-2496 1998; 
    PubMedGoogle Scholar
  • 3 Behr M, Schmitt T L, Espinoza C R, Loos U. Cloning of a functional promoter of the human sodium/iodide-symporter gene.  Biochem J. 331 359-363 1998; 
    PubMedGoogle Scholar
  • 4 Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart J M. Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study.  J Clin Endocrinol Metab. 83 4102-4106 1998; 
    CrossrefPubMedGoogle Scholar
  • 5 Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter.  Nature. 379 458-460 1996; 
    CrossrefPubMedGoogle Scholar
  • 6 Filetti S, Bidart J M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.  Eur J Endocrinol. 141 443-457 1999; 
    CrossrefPubMedGoogle Scholar
  • 7 Goretzki P E, Frilling A, Simon D, Roeher H D. Growth regulation of normal thyroids and thyroid tumors in man.  Recent Results Cancer Res. 118 48-63 1990; 
    PubMedGoogle Scholar
  • 8 Hundahl S A, Fleming I D, Fremgen A M, Menck H R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995.  Cancer. 83 2638-2648 1998; 
    CrossrefPubMedGoogle Scholar
  • 9 Kawaguchi A, Ikeda M, Endo T, Kogai T, Miyazaki A, Onaya T. Transforming growth factor-beta1 suppresses thyrotropin-induced Na+/I- symporter messenger RNA and protein levels in FRTL-5 rat thyroid cells.  Thyroid. 7 789-794 1997; 
    PubMedGoogle Scholar
  • 10 Lazar V, Bidart J M, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.  J Clin Endocrinol Metab. 84 3228-3234 1999; 
    PubMedGoogle Scholar
  • 11 Mandell R B, Mandell L Z, Link C JJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.  Cancer Res. 59 661-668 1999; 
    PubMedGoogle Scholar
  • 12 Morris J C, Kim C K, Padilla M L, Mechanick J I. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy.  Thyroid. 7 63-66 1997; 
    PubMedGoogle Scholar
  • 13 Pelikan D M, Lion H L, Hermans J, Goslings B M. The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma.  Clin Endocrinol (Oxf ). 47 713-720 1997; 
    CrossrefPubMedGoogle Scholar
  • 14 Schlumberger M J. Papillary and follicular thyroid carcinoma.  N Engl J Med. 338 297-306 1998; 
    CrossrefPubMedGoogle Scholar
  • 15 Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.  Biochem Biophys Res Commun. 240 832-838 1997; 
    CrossrefPubMedGoogle Scholar
  • 16 Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene.  Endocrinology. 138 4493-4496 1997; 
    CrossrefPubMedGoogle Scholar
  • 17 Simon D, Kohrle J, Schmutzler C, Mainz K, Reiners C, Roher H D. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.  Exp Clin Endocrinol Diabetes 104 ((Suppl 4)) 13-15 1996; 
    PubMedGoogle Scholar
  • 18 Smanik P A, Liu Q, Furminger T L, Ryu K, Xing S, Mazzaferri E L, Jhiang S M. Cloning of the human sodium iodide symporter.  Biochem Biophys Res Commun. 226 339-345 1996; 
    CrossrefPubMedGoogle Scholar
  • 19 Smanik P A, Ryu K Y, Theil K S, Mazzaferri E L, Jhiang S M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter.  Endocrinology. 138 3555-3558 1997; 
    CrossrefPubMedGoogle Scholar
  • 20 Smit J W, Vielvoye G J, Goslings B M. Embolization for vertebral metastases of follicular thyroid carcinoma.  J Clin Endocrinol Metab. 85 989-994 2000; 
    CrossrefPubMedGoogle Scholar
  • 21 Spitzweg C, Zhang S, Bergert E R, Castro M R, McIver B, Heufelder A E, Tindall D J, Young C Y, Morris J C. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.  Cancer Res. 59 2136-2141 1999; 
    PubMedGoogle Scholar
  • 22 Tong Q, Ryu K Y, Jhiang S M. Promoter characterization of the rat Na+/I- symporter gene.  Biochem Biophys Res Commun. 239 34-41 1997; 
    CrossrefPubMedGoogle Scholar
  • 23 Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont J E, Miot F. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I- symporter mRNAs in dog thyroid.  Mol Cell Endocrinol. 131 195-203 1997; 
    CrossrefPubMedGoogle Scholar
  • 24 Van Bezooijen R L, Farih-Sips H C, Papapoulos S E, Lowik C W. IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice.  J Bone Miner Res. 13 185-194 1998; 
    PubMedGoogle Scholar
  • 25 Venkataraman G M, Yatin M, Marcinek R, Ain K B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.  J Clin Endocrinol Metab. 84 2449-2457 1999; 
    CrossrefPubMedGoogle Scholar

Jan W. A. Smit

Department of Endocrinology, C4-R

Leiden University Medical Center

P.O. Box 9600

NL-2300 RC Leiden

The Netherlands

Telefon: + 31-7 15 26 30 82

Fax: + 31-7 15 24 81 36

eMail: j.w.a.smit.endo@lumc.nl